Evidence map›Paper›PMID 42680674›Full record

ReviewTrends in parasitology2026

Equitable access to monoclonal antibodies targeting parasites.

Sahal Thahir, Natalie M Bowman, Peter D Crompton, Robert A Seder, Kassoum Kayentao, Tuan M Tran

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Trends in parasitology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sahal ThahirDivision of Infectious Diseases, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Natalie M BowmanDivision of Infectious Diseases, Department of Medicine, University of North Carolina Chapel Hill, Chapel Hill, NC, USA.
Peter D CromptonMalaria Infection Biology and Immunity Section, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.
Robert A SederVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Kassoum KayentaoParasites and Microbes Research & Training Centre, Université des Sciences, des Techniques et des Technologies de Bamako, Bamako, Mali.
Tuan M TranDivision of Infectious Diseases, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA; Ryan White Center for Pediatric Infectious Disease and Global Health, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA. Electronic address: tuantran@iu.edu.

Funding

A systems analysis to understand the differential pharmacokinetics and protective efficacy of anti-malarial monoclonal antibodies in field trials.R01AI192628 · NIAID · INDIANA UNIVERSITY INDIANAPOLIS · PI Tuan Manh Tran · 2025 to 2026
$1.6M
NIAID NIH HHS R01 AI192628
6 · The paper itself

Abstract

Monoclonal antibodies (mAbs) have reshaped prevention and treatment of infectious diseases. However, the development of mAbs against parasitic diseases that disproportionately impact populations in resource-limited settings has received lower priority. Recent trials in Africa show that long-acting mAbs can prevent Plasmodium falciparum infection in children and adults. Early studies suggest that mAb pharmacokinetics differ between malaria-endemic and nonendemic populations, with age and prior parasite exposure possibly affecting the minimum amount of mAb required for durable protection. We present evidence that antiparasitic mAb studies should account for fragment crystallizable receptor polymorphisms and host factors commonly found in endemic populations. We discuss economic and manufacturing barriers to accessing mAbs in resource-limited settings, which have implications for the future use of these promising interventions.

Indexed as

Antibodies, MonoclonalParasitic DiseasesAnimalsHumansAntibodies, Monoclonalantiparasiticsmalariamonoclonal antibodiesneonatal Fc receptorpharmacokinetics

Identifiers

PMID42680674
PMCPMC13631834

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.